[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,900,554
  • Shares Outstanding, K 107,352
  • Annual Sales, $ 761,410 K
  • Annual Income, $ 99,650 K
  • EBIT $ -8 M
  • EBITDA $ -11 M
  • 60-Month Beta 0.50
  • Price/Sales 11.74
  • Price/Cash Flow 92.22
  • Price/Book 14.01

Options Overview Details

View History
  • Implied Volatility 54.41% (-0.36%)
  • Historical Volatility 56.44%
  • IV Percentile 44%
  • IV Rank 17.31%
  • IV High 138.94% on 12/15/25
  • IV Low 36.71% on 08/28/25
  • Expected Move (DTE 4) 2.36 (2.85%)
  • Put/Call Vol Ratio 2.38
  • Today's Volume 142
  • Volume Avg (30-Day) 1,663
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 29,530
  • Open Int (30-Day) 24,262
  • Expected Range 80.55 to 85.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.04
  • Number of Estimates 3
  • High Estimate $0.02
  • Low Estimate $-0.09
  • Prior Year $0.29
  • Growth Rate Est. (year over year) -113.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.30 +55.55%
on 05/13/26
84.79 -2.22%
on 06/12/26
+31.75 (+62.06%)
since 05/12/26
3-Month
31.81 +160.64%
on 03/13/26
84.79 -2.22%
on 06/12/26
+50.52 (+155.97%)
since 03/12/26
52-Week
28.66 +189.29%
on 02/19/26
91.00 -8.89%
on 10/08/25
+11.73 (+16.48%)
since 06/12/25

Most Recent Stories

More News
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

New data from CATALYST and MOMENTUM trials presented at American Diabetes Association’s (ADA) 86 th Scientific Sessions In the CATALYST trial, patients with...

CORT : 82.91 (-0.41%)
1 of Wall Street’s Favorite Stocks with Exciting Potential and 2 We Question

1 of Wall Street’s Favorite Stocks with Exciting Potential and 2 We Question

CORT : 82.91 (-0.41%)
CENT : 42.85 (+1.11%)
G : 32.06 (+0.53%)
Corcept Presents New Data at ASCO 2026: Lifyorliâ„¢ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic...

CORT : 82.91 (-0.41%)
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic...

CORT : 82.91 (-0.41%)
S&P 500 and Nasdaq 100 Post New Record Highs on Chip Stock Strength

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up +0.58%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.04%. June E-mini...

GOOGL : 359.68 (+0.53%)
AAPL : 291.13 (-1.52%)
INTU : 276.73 (-0.07%)
ADI : 417.79 (+1.37%)
F : 14.84 (+0.88%)
WIX : 45.91 (+4.18%)
AKAM : 133.50 (+0.79%)
TXN : 301.12 (+1.35%)
$IUXX : 29,635.95 (+0.64%)
ASML : 1,863.55 (-1.89%)
ZNU26 : 109-270 (+0.30%)
MSFT : 390.74 (+0.10%)
Chip Stock Strength Lifts the Broader Market

The S&P 500 Index ($SPX ) (SPY ) today is up +0.18%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.58%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.60%. June E-mini S&P futures (ESM26...

ADI : 417.79 (+1.37%)
WIX : 45.91 (+4.18%)
AKAM : 133.50 (+0.79%)
TXN : 301.12 (+1.35%)
$IUXX : 29,635.95 (+0.64%)
ZNU26 : 109-270 (+0.30%)
DT : 40.75 (+0.94%)
ESM26 : 7,498.50 (+0.85%)
QCOM : 211.72 (+4.32%)
$DOWI : 51,202.26 (+0.70%)
SPY : 741.75 (+0.54%)
DIA : 513.06 (+0.73%)
Stocks Pressured by Signs of Resurgent Inflation

The S&P 500 Index ($SPX ) (SPY ) today is down -0.19%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.05%. June E-mini S&P futures (ESM26...

ADI : 417.79 (+1.37%)
WIX : 45.91 (+4.18%)
AKAM : 133.50 (+0.79%)
$IUXX : 29,635.95 (+0.64%)
ZNU26 : 109-270 (+0.30%)
DT : 40.75 (+0.94%)
ESM26 : 7,498.50 (+0.85%)
LRCX : 366.81 (+1.18%)
$DOWI : 51,202.26 (+0.70%)
SPY : 741.75 (+0.54%)
DIA : 513.06 (+0.73%)
ON : 116.79 (+0.72%)
3 Reasons to Sell CORT and 1 Stock to Buy Instead

3 Reasons to Sell CORT and 1 Stock to Buy Instead

CORT : 82.91 (-0.41%)
3 High-Flying Stocks We Think Twice About

3 High-Flying Stocks We Think Twice About

CORT : 82.91 (-0.41%)
HIMX : 17.70 (+0.11%)
WMT : 121.04 (+0.45%)
CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures

CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures

CORT : 82.91 (-0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone),...

See More

Key Turning Points

3rd Resistance Point 86.72
2nd Resistance Point 85.75
1st Resistance Point 84.33
Last Price 82.91
1st Support Level 81.95
2nd Support Level 80.98
3rd Support Level 79.56

See More

52-Week High 91.00
Last Price 82.91
Fibonacci 61.8% 67.19
Fibonacci 50% 59.83
Fibonacci 38.2% 52.47
52-Week Low 28.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.